The 5-year OS rates for patients with CD5+vs. CD5− DLBCL were 35.5% vs. 64.8%, and the 5-year PFS rates for patients with CD5+vs. CD5− DLBCL were 29.6% vs. 59%, respectively. Here, CD5 is linked to diffuse large B-cell lymphoma.